Bristol-Myers scores 2 more immuno-oncology deals as ASCO approaches

Bristol-Myers Squibb ($BMY) inked a pair of deals to broaden its immuno-oncology efforts: It will partner with Incyte ($INCY) in testing the latter's drug candidate INCB24360 with its own PD-1 drug nivolumab. And it agreed to pay up to $1.24 billion to CytomX in a deal for up to four new "probody" drug candidates. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.